GoodRx Q4 revenue $196.6M; net loss $25.9M; adj. EBITDA $57.3M

GoodRx Holdings, Inc.

2023-FY EPS reported -$0.02 revenue$750,265,000

Q4 2023 revenue $196.6M, net loss $25.9M (13.2% margin), adjusted net income $31.1M (15.8% margin).
Full year 2023 revenue $750.3M, net loss $8.9M, adjusted EBITDA $217.4M (28.6% margin).
Q4 net cash from operations $15.9M; exited with over 7M consumers of prescription offerings.
Interim CEO Scott Wagner expects continued topline growth in Q1 and full year 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GoodRx Holdings, Inc. reported financial results for the three months and year ended December 31, 2023.

Period: the three months and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, GoodRx Holdings, Inc. (the “Company”) announced the Company’s financial results for the three months and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this report.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.